Literature DB >> 18565522

Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome.

Manuel Luque-Ramírez1, Covadonga Mendieta-Azcona, Francisco Alvarez-Blasco, Héctor F Escobar-Morreale.   

Abstract

OBJECTIVE: To compare the effects of metformin versus an antiandrogenic contraceptive pill on ambulatory blood pressure monitoring (ABPM) and carotid intima media thickness (CIMT) in women with polycystic ovary syndrome (PCOS).
DESIGN: Clinical randomized trial.
SETTING: Academic hospital. PATIENT(S): Thirty-four consecutive PCOS patients. INTERVENTION(S): PCOS patients randomized to oral treatment with metformin (n = 19) or with Diane(35) Diario pill (n = 15) for 24 weeks. MAIN OUTCOME MEASURE(S): ABPM recordings and ultrasound measurements of CIMT as marker of subclinical atherosclerosis obtained at baseline and after treatment. RESULT(S): Metformin resulted in reductions in daytime and 24-hour average systolic and diastolic blood pressure whereas Diane(35) Diario induced a slight increase in these parameters. Compared with a nonhyperandrogenic control group, the increased CIMT values of PCOS patients decreased to the normal range after treatment with either metformin or Diane(35) Diario. CONCLUSION(S): Metformin treatment decreased daytime ABPM recordings whereas Diane(35) Diario exerted the opposite effect. The safer blood pressure profile of metformin should be considered in PCOS patients who present with a history of hypertension or who are at risk for this disorder. Treatment with either Diane(35) Diario or metformin improved CIMT mean values.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565522     DOI: 10.1016/j.fertnstert.2008.03.082

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

2.  Role of metformin in the management of polycystic ovary syndrome.

Authors:  Hany Lashen
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

3.  Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.

Authors:  Eloise Fraison; Elena Kostova; Lisa J Moran; Sophia Bilal; Carolyn C Ee; Christos Venetis; Michael F Costello
Journal:  Cochrane Database Syst Rev       Date:  2020-08-13

Review 4.  Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.

Authors:  Krystallenia I Alexandraki; Eleni A Kandaraki; Kalliopi-Anna Poulia; Christina Piperi; Eirini Papadimitriou; Theodoros G Papaioannou
Journal:  touchREV Endocrinol       Date:  2021-04-28

5.  Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis.

Authors:  Farshad Forouzandeh; Gloria Salazar; Nikolay Patrushev; Shiqin Xiong; Lula Hilenski; Baowei Fei; R Wayne Alexander
Journal:  J Am Heart Assoc       Date:  2014-12       Impact factor: 5.501

6.  Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

Authors:  Jacob D Peuler; Laura E Phelps
Journal:  J Smooth Muscle Res       Date:  2015

7.  Bloodletting has no effect on the blood pressure abnormalities of hyperandrogenic women taking oral contraceptives in a randomized clinical trial.

Authors:  Manuel Luque-Ramírez; Andrés E Ortiz-Flores; Lía Nattero-Chávez; M Ángeles Martínez-García; María Insenser; Francisco Álvarez-Blasco; Elena Fernández-Durán; Alejandra Quintero-Tobar; Sara de Lope Quiñones; Héctor F Escobar-Morreale
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379

Review 8.  Assessing blood pressure responses to noncardiovascular drugs: the beneficial role of ambulatory blood pressure monitoring.

Authors:  Eoin O'Brien; J Rick Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-11       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.